Click here to get full coverage on Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com

Immunome (IMNM) CEO Siegall buys $100k in shares  Investing.com

Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com

Click here to get full coverage on Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat

Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock  MarketBeat

Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat

Click here to get full coverage on Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application  Yahoo Finance

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Click here to get full coverage on Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (IMNM) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (IMNM) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM)  The Globe and Mail

Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM) - The Globe and Mail

Click here to get full coverage on Why Is IMNM Stock Rising Today? - Stocktwits

Why Is IMNM Stock Rising Today?  Stocktwits

Why Is IMNM Stock Rising Today? - Stocktwits

Click here to get full coverage on Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks

Here’s Why Immunome Stock (IMNM) Soared Over 20% Today  TipRanks

Here’s Why Immunome Stock (IMNM) Soared Over 20% Today - TipRanks

Click here to get full coverage on Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares - Quiver Quantitative

Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares  Quiver Quantitative

Insider Purchase: President and CEO of $IMNM Buys 46,511 Shares - Quiver Quantitative

Click here to get full coverage on The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily

The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying  Investor's Business Daily

The 'Knockout' Hit That Sent This Top 3% Biotech Stock Flying - Investor's Business Daily

Click here to get full coverage on Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - ts2.tech

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)  ts2.tech

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025) - ts2.tech

Click here to get full coverage on Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors  Business Wire

Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Click here to get full coverage on Friday 12/19 Insider Buying Report: IMNM, S - Nasdaq

Friday 12/19 Insider Buying Report: IMNM, S  Nasdaq

Friday 12/19 Insider Buying Report: IMNM, S - Nasdaq

Click here to get full coverage on Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy?  Yahoo Finance

Will Immunome's (IMNM) Antibody Collaboration Refocus Its Pipeline Expansion Strategy? - Yahoo Finance

Click here to get full coverage on Siegall buys Immunome (IMNM) shares worth $149k - Investing.com

Siegall buys Immunome (IMNM) shares worth $149k  Investing.com

Siegall buys Immunome (IMNM) shares worth $149k - Investing.com

Click here to get full coverage on Immunome Announces Proposed Public Offering of Common Stock - Business Wire

Immunome Announces Proposed Public Offering of Common Stock  Business Wire

Immunome Announces Proposed Public Offering of Common Stock - Business Wire

Click here to get full coverage on Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains?  Yahoo Finance

Immunome (IMNM) Surges 6.1%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results  Quiver Quantitative

Immunome Inc. Stock (IMNM) Opinions on Phase 3 RINGSIDE Trial Results - Quiver Quantitative

Click here to get full coverage on Noteworthy Monday Option Activity: MO, IMNM, RSI - Nasdaq

Noteworthy Monday Option Activity: MO, IMNM, RSI  Nasdaq

Noteworthy Monday Option Activity: MO, IMNM, RSI - Nasdaq

Click here to get full coverage on Insider Buying: Clay Siegall Acquires Additional Shares of Immunome Inc (IMNM) - GuruFocus

Insider Buying: Clay Siegall Acquires Additional Shares of Immunome Inc (IMNM)  GuruFocus

Insider Buying: Clay Siegall Acquires Additional Shares of Immunome Inc (IMNM) - GuruFocus

Click here to get full coverage on Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM) - Seeking Alpha

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM)  Seeking Alpha

Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat (IMNM) - Seeking Alpha

Click here to get full coverage on Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm

Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise  Sahm

Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - Sahm

Click here to get full coverage on Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - ts2.tech

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)  ts2.tech

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025) - ts2.tech

Click here to get full coverage on Immunome Announces Pricing of Public Offering of Common Stock - Business Wire

Immunome Announces Pricing of Public Offering of Common Stock  Business Wire

Immunome Announces Pricing of Public Offering of Common Stock - Business Wire

Click here to get full coverage on Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%  Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Click here to get full coverage on Why Immunome Stock Surged Today - The Motley Fool

Why Immunome Stock Surged Today  The Motley Fool

Why Immunome Stock Surged Today - The Motley Fool

Click here to get full coverage on First Week of IMNM February 2026 Options Trading - Nasdaq

First Week of IMNM February 2026 Options Trading  Nasdaq

First Week of IMNM February 2026 Options Trading - Nasdaq

Click here to get full coverage on Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors  Business Wire

Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates  Yahoo Finance

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on $IMNM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 8% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 8% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more  CNBC

Stocks making the biggest moves midday: Zillow, KLA, iRobot, Immunome & more - CNBC

Click here to get full coverage on Natixis Invests $2.13 Million in Immunome, Inc. $IMNM - MarketBeat

Natixis Invests $2.13 Million in Immunome, Inc. $IMNM  MarketBeat

Natixis Invests $2.13 Million in Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Immunome (NASDAQ:IMNM) Shares Gap Down - What's Next? - MarketBeat

Immunome (NASDAQ:IMNM) Shares Gap Down - What's Next?  MarketBeat

Immunome (NASDAQ:IMNM) Shares Gap Down - What's Next? - MarketBeat

Click here to get full coverage on Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM - MarketBeat

Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM  MarketBeat

Birchview Capital LP Takes $558,000 Position in Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat

Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock  MarketBeat

Immunome (NASDAQ:IMNM) Insider Purchases $204,900.00 in Stock - MarketBeat

Click here to get full coverage on Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares  MarketBeat

Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares - MarketBeat

Click here to get full coverage on Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases 7,278 Shares of Stock - MarketBeat

Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases 7,278 Shares of Stock  MarketBeat

Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases 7,278 Shares of Stock - MarketBeat

Click here to get full coverage on Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - simplywall.st

Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise  simplywall.st

Immunome (IMNM): Assessing Valuation After Strong Phase 3 Varegacestat Data and $400 Million Equity Raise - simplywall.st

Click here to get full coverage on Guggenheim Remains a Buy on Immunome (IMNM) - The Globe and Mail

Guggenheim Remains a Buy on Immunome (IMNM)  The Globe and Mail

Guggenheim Remains a Buy on Immunome (IMNM) - The Globe and Mail

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail

Click here to get full coverage on Immunome stock falls after pricing $400 million share offering - Investing.com

Immunome stock falls after pricing $400 million share offering  Investing.com

Immunome stock falls after pricing $400 million share offering - Investing.com

Click here to get full coverage on Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC - MarketBeat

Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC  MarketBeat

Immunome, Inc. $IMNM Stock Holdings Decreased by Redmile Group LLC - MarketBeat

Click here to get full coverage on Immunome (NASDAQ:IMNM) Stock Price Up 9.5% - Time to Buy? - MarketBeat

Immunome (NASDAQ:IMNM) Stock Price Up 9.5% - Time to Buy?  MarketBeat

Immunome (NASDAQ:IMNM) Stock Price Up 9.5% - Time to Buy? - MarketBeat

Click here to get full coverage on Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)  Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Immunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy? - MarketBeat

Immunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy?  MarketBeat

Immunome (NASDAQ:IMNM) Shares Gap Up - Still a Buy? - MarketBeat

Click here to get full coverage on Immunome Target of Unusually High Options Trading (NASDAQ:IMNM) - MarketBeat

Immunome Target of Unusually High Options Trading (NASDAQ:IMNM)  MarketBeat

Immunome Target of Unusually High Options Trading (NASDAQ:IMNM) - MarketBeat

Click here to get full coverage on Marshall Wace LLP Sells 312,956 Shares of Immunome, Inc. $IMNM - MarketBeat

Marshall Wace LLP Sells 312,956 Shares of Immunome, Inc. $IMNM  MarketBeat

Marshall Wace LLP Sells 312,956 Shares of Immunome, Inc. $IMNM - MarketBeat

Click here to get full coverage on Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com South Africa

Siegall buys Immunome (IMNM) shares worth $149k By Investing.com  Investing.com South Africa

Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com South Africa

Click here to get full coverage on Immunome (NASDAQ:IMNM) Reaches New 1-Year High - Time to Buy? - MarketBeat

Immunome (NASDAQ:IMNM) Reaches New 1-Year High - Time to Buy?  MarketBeat

Immunome (NASDAQ:IMNM) Reaches New 1-Year High - Time to Buy? - MarketBeat

Click here to get full coverage on Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks

Top Executive Makes Bold Move With Fresh Immunome Stock Purchase  TipRanks

Top Executive Makes Bold Move With Fresh Immunome Stock Purchase - TipRanks

Click here to get full coverage on Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R - GuruFocus

Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R  GuruFocus

Goldman Sachs Initiates Coverage on Immunome (IMNM) with 'Buy' R - GuruFocus

Click here to get full coverage on Immunome (NASDAQ:IMNM) Hits New 12-Month High - Here's Why - MarketBeat

Immunome (NASDAQ:IMNM) Hits New 12-Month High - Here's Why  MarketBeat

Immunome (NASDAQ:IMNM) Hits New 12-Month High - Here's Why - MarketBeat

Click here to get full coverage on Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug - Nasdaq

Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug  Nasdaq

Immunome Stock Surges 20% After Positive Phase 3 Data For Desmoid Tumor Drug - Nasdaq

Click here to get full coverage on Immunome (IMNM) Is Up 15.3% After Desmoid Tumor Phase 3 Win and NDA Timeline Update – Has The Bull Case Changed? - simplywall.st

Immunome (IMNM) Is Up 15.3% After Desmoid Tumor Phase 3 Win and NDA Timeline Update – Has The Bull Case Changed?  simplywall.st

Immunome (IMNM) Is Up 15.3% After Desmoid Tumor Phase 3 Win and NDA Timeline Update – Has The Bull Case Changed? - simplywall.st

Click here to get full coverage on Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Australia

Siegall buys Immunome (IMNM) shares worth $149k By Investing.com  Investing.com Australia

Siegall buys Immunome (IMNM) shares worth $149k By Investing.com - Investing.com Australia

Click here to get full coverage on Immunome(IMNM.US) Director Sells US$8.33 Million in Common Stock - 富途牛牛

Immunome(IMNM.US) Director Sells US$8.33 Million in Common Stock  富途牛牛

Immunome(IMNM.US) Director Sells US$8.33 Million in Common Stock - 富途牛牛

Click here to get full coverage on What's Going On With Immunome Shares Monday? - Sahm

What's Going On With Immunome Shares Monday?  Sahm

What's Going On With Immunome Shares Monday? - Sahm

Click here to get full coverage on Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?  Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Click here to get full coverage on Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Nasdaq

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet  Nasdaq

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Nasdaq

Click here to get full coverage on Immunome Inc Announces Follow-On Public Offering - TradingView — Track All Markets

Immunome Inc Announces Follow-On Public Offering  TradingView — Track All Markets

Immunome Inc Announces Follow-On Public Offering - TradingView — Track All Markets

Click here to get full coverage on Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy - FinancialContent

ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy  FinancialContent

ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy - FinancialContent

Click here to get full coverage on Breakthrough Antibody Discovery Alliance: Infinimmune Teams with Immunome Using GLIMPSE Platform - Stock Titan

Breakthrough Antibody Discovery Alliance: Infinimmune Teams with Immunome Using GLIMPSE Platform  Stock Titan

Breakthrough Antibody Discovery Alliance: Infinimmune Teams with Immunome Using GLIMPSE Platform - Stock Titan

Click here to get full coverage on Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update  Business Wire

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference  Business Wire

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference - Business Wire

Click here to get full coverage on Guggenheim Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛

Guggenheim Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $35  富途牛牛

Guggenheim Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛

Click here to get full coverage on Immunome stock surges after positive Phase 3 trial results By Investing.com - Investing.com South Africa

Immunome stock surges after positive Phase 3 trial results By Investing.com  Investing.com South Africa

Immunome stock surges after positive Phase 3 trial results By Investing.com - Investing.com South Africa

Click here to get full coverage on Immunome stock hits 52-week high at $20.50 - Investing.com

Immunome stock hits 52-week high at $20.50  Investing.com

IMNM

Price Chart

Key Statistics

Technicals

About IMNM

Latest News

Immunome (IMNM) CEO Siegall buys $100k in shares - Investing.com

Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock - MarketBeat

Immunome (IMNM) Valuation After Breakthrough Phase 3 RINGSIDE Results and Planned FDA New Drug Application - Yahoo Finance

Advanced Charts

Top Gainers

Top Losers